Department of Cardionephrology, University of Genoa, Azienda Ospedaliera Universitaria San Martino, Genoa, Italy.
Clin J Am Soc Nephrol. 2010 Jun;5(6):1099-106. doi: 10.2215/CJN.07271009. Epub 2010 Apr 29.
Increased urinary albumin excretion is a known risk factor for cardiovascular events and clinical nephropathy in patients with diabetes. Whether microalbuminuria predicts long-term development of chronic renal insufficiency (CRI) in patients without diabetes and with primary hypertension remains to be documented.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted an 11.8-year follow-up of 917 patients who did not have diabetes and had hypertension and were enrolled in the Microalbuminuria: A Genoa Investigation on Complications (MAGIC) cohort between 1993 and 1997. Urinary albumin-to-creatinine ratio (ACR) was assessed at baseline in untreated patients in a core laboratory. Microalbuminuria was defined as ACR > or =22 mg/g in men and ACR > or =31 mg/g in women.
A total of 10,268 person-years of follow-up revealed that baseline microalbuminuria was associated with an increased risk for developing CRI (relative risk [RR] 7.61; 95% confidence interval [CI] 3.19 to 8.16; P < 0.0001), cardiovascular events (composite of fatal and nonfatal cardiac and cerebrovascular events; RR 2.11; 95% CI 1.08 to 4.13; P < 0.028), and cardiorenal events (composite of former end points; RR 3.21; 95% CI 1.86 to 5.53; P < 0.0001). Microalbuminuria remained significantly related to CRI (RR 12.75; 95% CI 3.62 to 44.92; P < 0.0001) and cardiorenal events (RR 2.58; 95% CI 1.32 to 5.05; P = 0.0056) even after adjustment for several baseline covariates.
Microalbuminuria is an independent predictor of renal and cardiovascular complications in patients without diabetes and with primary hypertension.
尿白蛋白排泄增加是糖尿病患者发生心血管事件和临床肾病的已知危险因素。微量白蛋白尿是否可预测无糖尿病和原发性高血压患者的慢性肾功能不全(CRI)的长期发展,仍有待记录。
设计、设置、参与者和测量:我们对 1993 年至 1997 年间参加微白蛋白尿:热那亚并发症研究(MAGIC)队列的 917 例无糖尿病和高血压的患者进行了 11.8 年的随访。在核心实验室对未经治疗的患者进行基线时的尿白蛋白与肌酐比值(ACR)评估。微量白蛋白尿定义为男性 ACR≥22mg/g 和女性 ACR≥31mg/g。
总共 10268 人年的随访显示,基线微量白蛋白尿与发生 CRI 的风险增加相关(相对风险 [RR] 7.61;95%置信区间 [CI] 3.19 至 8.16;P<0.0001)、心血管事件(致命和非致命性心脏和脑血管事件的综合结果;RR 2.11;95%CI 1.08 至 4.13;P<0.028)和心肾事件(前者终点的综合结果;RR 3.21;95%CI 1.86 至 5.53;P<0.0001)。即使在调整了几个基线协变量后,微量白蛋白尿与 CRI(RR 12.75;95%CI 3.62 至 44.92;P<0.0001)和心肾事件(RR 2.58;95%CI 1.32 至 5.05;P=0.0056)仍有显著相关性。
微量白蛋白尿是无糖尿病和原发性高血压患者肾脏和心血管并发症的独立预测因子。